🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Inhibikase Therapeutics ends agreement with sales agent

Published 2024-12-05, 05:10 p/m
IKT
-

Inhibikase Therapeutics, Inc., a company specializing in biological products, has terminated a material definitive agreement with H.C. Wainwright & Co., LLC, according to a recent SEC filing. The At the Market Offering Agreement (ATM Agreement), established on February 1, 2024, allowed Inhibikase to sell shares of its common stock through the sales agent.

Under the agreement, the company had the option to issue and sell shares worth up to $5,659,255. It successfully sold 315,338 shares for a gross sales price of approximately $849,187.85. Despite current financial challenges, the stock has shown remarkable performance, with a 164% return over the past year. On May 20, 2024, Inhibikase filed a prospectus supplement to reduce the maximum aggregate gross sales price of the stock that could be offered to $50,000, excluding the shares already sold, after which no further sales occurred.

Inhibikase Therapeutics, headquartered in Atlanta, Georgia, is listed on The Nasdaq Stock Market LLC under the ticker NASDAQ:IKT. InvestingPro analysis indicates the stock is currently overvalued, though analysts maintain price targets ranging from $5 to $8 per share. The company's decision to end the ATM Agreement is a significant change in its approach to financing its operations and projects. Discover more insights and 8 additional ProTips with an InvestingPro subscription.

In other recent news, Inhibikase Therapeutics has secured approximately $110 million in private placement financing, led by Soleus Capital and other investors. This funding is expected to support the initiation of a Phase 2b trial for its lead drug candidate, IkT-001Pro, for pulmonary arterial hypertension (PAH). Concurrently, the company has reported a net loss of $5.0 million for the second quarter, with H.C. Wainwright adjusting its full-year 2024 earnings per share (EPS) forecast for Inhibikase to ($2.75), a decrease from the prior estimate.

Jefferies has initiated coverage on Inhibikase Therapeutics with a Buy rating, citing the potential of IkT-001Pro and the firm's strong financial position. However, H.C. Wainwright has revised its outlook on the company, reducing the price target to $5.00 from the previous $15.00, while maintaining a Buy recommendation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.